Following Connecticut’s 2023 legislative session, Governor Ned Lamont announced a series of policy initiatives intended to lower health care costs, a campaign developed in partnership with the Connecticut Hospital Association. Most notably, “An Act Protecting Patients and Prohibiting Unnecessary Health Care Costs” (the Act) was introduced, passed by the Connecticut Legislature in early June and signed into law by Governor Lamont in late June. This Act implements a portion of those initiatives.
The Act particularly narrows in on the practices of drug and device manufacturers who employ sales representatives, subjecting them to increased scrutiny and regulation. This forms a critical part of the overarching efforts to counter the hiked costs of health care. Echoing a trend that spans across multiple states in recent years, this legislation underscores the sustained attention on the pharmaceutical and medical devices sectors from lawmakers of varying jurisdictions. The law’s provisions serve as a basis for both the protection of patients and the prohibition of unnecessary health costs.
While the details of the law are still being discussed, it’s notable for the corporations and firms in the corresponding arenas who must manage its potential consequences. Legal teams will need to review the Act’s implications for their clients and ascertain an appropriate course of action.
For more information on the specifics of “An Act Protecting Patients and Prohibiting Unnecessary Health Care Costs” and the related legal implications, you can read the full details here.